Page last updated: 2024-11-11

leukadherin-1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

leukadherin-1: enhances the interaction between ICAM-1 and CD11b/CD18; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5342077
SCHEMBL ID46211
SCHEMBL ID18301010
MeSH IDM000595866

Synonyms (36)

Synonym
bdbm8427
4-(5-{[(5z)-3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}furan-2-yl)benzoic acid
BIM-0028118.P001
LA1 ,
4-{5-[(z)-(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzoic acid
STL372026
S8306
AB00093225-01
SCHEMBL46211
HY-15701
CS-5911
leukadherin-1
344897-95-6
4-[(5-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]benzoic acid
leukadherin 1
AC-33019
AKOS024458420
SCHEMBL18301010
4-[5-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-benzoic acid
BCP18444
EX-A2398
(z)-leukadherin-1
AS-16501
4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
NCGC00263554-08
2055362-72-4
(z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
CCG-268900
C74771
A899625
(z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoicacid
unii-hf23i3uyo2
adh503 free acid
benzoic acid, 4-(5-((z)-(4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene)methyl)-2-furanyl)-
gb-1275 free acid
hf23i3uyo2 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lethal factorBacillus anthracisIC50 (µMol)6.00000.09702.85976.0000AID1796190
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1796190Fluorescence Peptide Cleavage Assay from Article 10.1073/pnas.0502733102: \\Efficient synthetic inhibitors of anthrax lethal factor.\\2005Proceedings of the National Academy of Sciences of the United States of America, Jul-05, Volume: 102, Issue:27
Efficient synthetic inhibitors of anthrax lethal factor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's8 (57.14)24.3611
2020's5 (35.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.18 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]